Fibrin gels engineered with pro-angiogenic growth factors promote engraftment of pancreatic islets in extrahepatic sites in mice

Mejdi Najjar, Vita Manzoli, Maria Abreu, Chiara Villa, Mikaël M. Martino, Ruth Molano, Yvan Torrente, Antonello Pileggi, Luca A Inverardi, Camillo Ricordi, Jeffrey A. Hubbell, Alice Tomei

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

With a view toward reduction of graft loss, we explored pancreatic islet transplantation within fibrin matrices rendered pro-angiogenic by incorporation of minimal doses of vascular endothelial growth factor-A165 and platelet-derived growth factor-BB presented complexed to a fibrin-bound integrin-binding fibronectin domain. Engineered matrices allowed for extended release of pro-angiogenic factors and for their synergistic signaling with extracellular matrix-binding domains in the post-transplant period. Aprotinin addition delayed matrix degradation and prolonged pro-angiogenic factor availability within the graft. Both subcutaneous (SC) and epididymal fat pad (EFP) sites were evaluated. We show that in the SC site, diabetes reversal in mice transplanted with 1,000 IEQ of syngeneic islets was not observed for islets transplanted alone, while engineered matrices resulted in a diabetes median reversal time (MDRT) of 38 days. In the EFP site, the MDRT with 250 IEQ of syngeneic islets within the engineered matrices was 24 days versus 86 days for islets transplanted alone. Improved function of engineered grafts was associated with enhanced and earlier (by day 7) angiogenesis. Our findings show that by engineering the transplant site to promote prompt re-vascularization, engraftment and long-term function of islet grafts can be improved in relevant extrahepatic sites.

Original languageEnglish (US)
Pages (from-to)1916-1926
Number of pages11
JournalBiotechnology and Bioengineering
Volume112
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Angiogenesis Inducing Agents
Fibrin
Islets of Langerhans
Intercellular Signaling Peptides and Proteins
Gels
Transplants
Grafts
Medical problems
Oils and fats
Adipose Tissue
Fats
Transplantation (surgical)
Islets of Langerhans Transplantation
Aprotinin
Subcutaneous Fat
Platelets
Fibronectins
Integrins
Vascular Endothelial Growth Factor A
Extracellular Matrix

Keywords

  • Angiogenesis
  • Hydrogels
  • Islet transplantation
  • Local release
  • PDGF-BB
  • VEGF-A

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Cite this

Fibrin gels engineered with pro-angiogenic growth factors promote engraftment of pancreatic islets in extrahepatic sites in mice. / Najjar, Mejdi; Manzoli, Vita; Abreu, Maria; Villa, Chiara; Martino, Mikaël M.; Molano, Ruth; Torrente, Yvan; Pileggi, Antonello; Inverardi, Luca A; Ricordi, Camillo; Hubbell, Jeffrey A.; Tomei, Alice.

In: Biotechnology and Bioengineering, Vol. 112, No. 9, 01.09.2015, p. 1916-1926.

Research output: Contribution to journalArticle

Najjar, M, Manzoli, V, Abreu, M, Villa, C, Martino, MM, Molano, R, Torrente, Y, Pileggi, A, Inverardi, LA, Ricordi, C, Hubbell, JA & Tomei, A 2015, 'Fibrin gels engineered with pro-angiogenic growth factors promote engraftment of pancreatic islets in extrahepatic sites in mice', Biotechnology and Bioengineering, vol. 112, no. 9, pp. 1916-1926. https://doi.org/10.1002/bit.25589
Najjar, Mejdi ; Manzoli, Vita ; Abreu, Maria ; Villa, Chiara ; Martino, Mikaël M. ; Molano, Ruth ; Torrente, Yvan ; Pileggi, Antonello ; Inverardi, Luca A ; Ricordi, Camillo ; Hubbell, Jeffrey A. ; Tomei, Alice. / Fibrin gels engineered with pro-angiogenic growth factors promote engraftment of pancreatic islets in extrahepatic sites in mice. In: Biotechnology and Bioengineering. 2015 ; Vol. 112, No. 9. pp. 1916-1926.
@article{b5aac1395bec4c21abb4aa34832021f1,
title = "Fibrin gels engineered with pro-angiogenic growth factors promote engraftment of pancreatic islets in extrahepatic sites in mice",
abstract = "With a view toward reduction of graft loss, we explored pancreatic islet transplantation within fibrin matrices rendered pro-angiogenic by incorporation of minimal doses of vascular endothelial growth factor-A165 and platelet-derived growth factor-BB presented complexed to a fibrin-bound integrin-binding fibronectin domain. Engineered matrices allowed for extended release of pro-angiogenic factors and for their synergistic signaling with extracellular matrix-binding domains in the post-transplant period. Aprotinin addition delayed matrix degradation and prolonged pro-angiogenic factor availability within the graft. Both subcutaneous (SC) and epididymal fat pad (EFP) sites were evaluated. We show that in the SC site, diabetes reversal in mice transplanted with 1,000 IEQ of syngeneic islets was not observed for islets transplanted alone, while engineered matrices resulted in a diabetes median reversal time (MDRT) of 38 days. In the EFP site, the MDRT with 250 IEQ of syngeneic islets within the engineered matrices was 24 days versus 86 days for islets transplanted alone. Improved function of engineered grafts was associated with enhanced and earlier (by day 7) angiogenesis. Our findings show that by engineering the transplant site to promote prompt re-vascularization, engraftment and long-term function of islet grafts can be improved in relevant extrahepatic sites.",
keywords = "Angiogenesis, Hydrogels, Islet transplantation, Local release, PDGF-BB, VEGF-A",
author = "Mejdi Najjar and Vita Manzoli and Maria Abreu and Chiara Villa and Martino, {Mika{\"e}l M.} and Ruth Molano and Yvan Torrente and Antonello Pileggi and Inverardi, {Luca A} and Camillo Ricordi and Hubbell, {Jeffrey A.} and Alice Tomei",
year = "2015",
month = "9",
day = "1",
doi = "10.1002/bit.25589",
language = "English (US)",
volume = "112",
pages = "1916--1926",
journal = "Biotechnology and Bioengineering",
issn = "0006-3592",
publisher = "Wiley-VCH Verlag",
number = "9",

}

TY - JOUR

T1 - Fibrin gels engineered with pro-angiogenic growth factors promote engraftment of pancreatic islets in extrahepatic sites in mice

AU - Najjar, Mejdi

AU - Manzoli, Vita

AU - Abreu, Maria

AU - Villa, Chiara

AU - Martino, Mikaël M.

AU - Molano, Ruth

AU - Torrente, Yvan

AU - Pileggi, Antonello

AU - Inverardi, Luca A

AU - Ricordi, Camillo

AU - Hubbell, Jeffrey A.

AU - Tomei, Alice

PY - 2015/9/1

Y1 - 2015/9/1

N2 - With a view toward reduction of graft loss, we explored pancreatic islet transplantation within fibrin matrices rendered pro-angiogenic by incorporation of minimal doses of vascular endothelial growth factor-A165 and platelet-derived growth factor-BB presented complexed to a fibrin-bound integrin-binding fibronectin domain. Engineered matrices allowed for extended release of pro-angiogenic factors and for their synergistic signaling with extracellular matrix-binding domains in the post-transplant period. Aprotinin addition delayed matrix degradation and prolonged pro-angiogenic factor availability within the graft. Both subcutaneous (SC) and epididymal fat pad (EFP) sites were evaluated. We show that in the SC site, diabetes reversal in mice transplanted with 1,000 IEQ of syngeneic islets was not observed for islets transplanted alone, while engineered matrices resulted in a diabetes median reversal time (MDRT) of 38 days. In the EFP site, the MDRT with 250 IEQ of syngeneic islets within the engineered matrices was 24 days versus 86 days for islets transplanted alone. Improved function of engineered grafts was associated with enhanced and earlier (by day 7) angiogenesis. Our findings show that by engineering the transplant site to promote prompt re-vascularization, engraftment and long-term function of islet grafts can be improved in relevant extrahepatic sites.

AB - With a view toward reduction of graft loss, we explored pancreatic islet transplantation within fibrin matrices rendered pro-angiogenic by incorporation of minimal doses of vascular endothelial growth factor-A165 and platelet-derived growth factor-BB presented complexed to a fibrin-bound integrin-binding fibronectin domain. Engineered matrices allowed for extended release of pro-angiogenic factors and for their synergistic signaling with extracellular matrix-binding domains in the post-transplant period. Aprotinin addition delayed matrix degradation and prolonged pro-angiogenic factor availability within the graft. Both subcutaneous (SC) and epididymal fat pad (EFP) sites were evaluated. We show that in the SC site, diabetes reversal in mice transplanted with 1,000 IEQ of syngeneic islets was not observed for islets transplanted alone, while engineered matrices resulted in a diabetes median reversal time (MDRT) of 38 days. In the EFP site, the MDRT with 250 IEQ of syngeneic islets within the engineered matrices was 24 days versus 86 days for islets transplanted alone. Improved function of engineered grafts was associated with enhanced and earlier (by day 7) angiogenesis. Our findings show that by engineering the transplant site to promote prompt re-vascularization, engraftment and long-term function of islet grafts can be improved in relevant extrahepatic sites.

KW - Angiogenesis

KW - Hydrogels

KW - Islet transplantation

KW - Local release

KW - PDGF-BB

KW - VEGF-A

UR - http://www.scopus.com/inward/record.url?scp=84937739152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937739152&partnerID=8YFLogxK

U2 - 10.1002/bit.25589

DO - 10.1002/bit.25589

M3 - Article

C2 - 25786390

AN - SCOPUS:84937739152

VL - 112

SP - 1916

EP - 1926

JO - Biotechnology and Bioengineering

JF - Biotechnology and Bioengineering

SN - 0006-3592

IS - 9

ER -